Skip to main content
logo
AstraZeneca PLC (AZN)
NYSE: AZN · Real-Time Price · USD
167.79
+3.84 (2.34%)
Oct 20, 2026, 10:33 AM EDT - Market open

AstraZeneca Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period Ending
Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Operating Revenue
15,38415,28815,50315,19114,45713,58814,89113,56512,93812,67912,02411,49211,41610,87911,20710,98210,77111,39012,0119,866
Revenue
15,38415,28815,50315,19114,45713,58814,89113,56512,93812,67912,02411,49211,41610,87911,20710,98210,77111,39012,0119,866
Revenue Growth (YoY)
6.41%12.51%4.11%11.99%11.74%7.17%23.84%18.04%13.33%16.55%7.29%4.64%5.99%-4.49%-6.69%11.31%31.03%55.60%62.09%49.98%
Cost of Revenue
2,5312,6733,1702,7922,4732,2412,1563,0812,1832,2182,0802,0951,9601,905-8722,9822,9983,5111,9873,757
Gross Profit
12,85312,61512,33312,39911,98411,34712,73510,48410,75510,4619,9449,3979,4568,97412,0798,0007,7737,87910,0246,109
Selling, General & Admin
5,7245,0275,3185,1965,0074,6274,4745,2885,0614,6303,7864,9295,1174,1934,0194,4034,8104,1904,0224,210
Research & Development
3,6723,4713,6153,6303,5483,1593,3373,1153,0082,7832,8872,5842,6672,3402,4362,4582,5462,2272,0412,438
Other Operating Expenses
-152-15553-89-79-47-38-25-60-67-70-70-784-100-71-106-122-62285-37
Operating Expenses
9,2448,3438,9868,7378,4767,7397,7738,3788,0097,3466,6037,4437,0006,4336,3846,7557,2346,3556,3486,611
Operating Income
3,6094,2723,3473,6623,5083,6084,9622,1062,7463,1153,3411,9542,4562,5415,6951,2455391,5243,676-502
Interest Expense
-435-393-155-434-439-349-139-457-443-413-38-392-431-365--339-311-336--335
Interest & Investment Income
8073135856884-18310011165101647810015181718915
Earnings From Equity Investments
-10-12-10-10-7-5-4-6-13--11-1--111-6-9-7
Currency Exchange Gain (Loss)
---31----42----34----16----20-
Other Non Operating Income (Expenses)
---247----134----292----370----478-
EBT Excluding Unusual Items
3,2443,9403,0493,3233,1273,3364,6421,8282,3972,8003,0421,6522,0882,2545,4089222471,1993,358-829
Merger & Restructuring Charges
-100-60-82-79---1,154----604----4,288----3,724-
Gain (Loss) on Sale of Assets
-34154--6660---51--241155---509-
Asset Writedown
-345--230----1,574----58---271-197--94-897-1,172
Legal Settlements
---218----48----1,013----14---775-48-
Other Unusual Items
---44----260----521--38-286--35166-
Pretax Income
2,7993,9142,6293,2443,1273,4021,6661,8282,3972,8008971,6522,0882,262778922247553-636-2,001
Income Tax Expense
291833300709679481166395469620-62274268458-124-720-113165-290-350
Earnings From Continuing Operations
2,5083,0812,3292,5352,4482,9211,5001,4331,9282,1809591,3781,8201,8049021,642360388-346-1,651
Minority Interest in Earnings
-1-1-3-22-5--4-1-11-4-2-1-1-2--2-1-1
Net Income
2,5073,0802,3262,5332,4502,9161,5001,4291,9272,1799601,3741,8181,8039011,640360386-347-1,652
Net Income to Common
2,5073,0802,3262,5332,4502,9161,5001,4291,9272,1799601,3741,8181,8039011,640360386-347-1,652
Net Income Growth (YoY)
2.33%5.62%55.07%77.26%27.14%33.82%56.25%4.00%6.00%20.85%6.55%-16.22%405.00%367.10%---34.54%-75.27%--
Shares Outstanding (Basic)
1,5511,5491,5511,5511,5501,5501,5501,5501,5491,5491,5491,5491,5501,5491,5491,5481,5491,5481,5471,496
Shares Outstanding (Diluted)
1,5601,5611,5631,5611,5591,5611,5621,5621,5601,5601,5611,5601,5601,5601,5591,5591,5601,5611,5471,496
Shares Change (YoY)
0.06%-0.06%-0.06%-0.06%0.06%0.06%0.13%--0.13%0.06%--0.06%0.78%4.21%18.36%18.35%17.82%13.94%
EPS (Basic)
1.621.991.501.631.581.880.970.921.241.410.620.891.171.160.581.060.230.25-0.22-1.10
EPS (Diluted)
1.611.971.481.621.571.870.960.911.231.400.610.881.171.160.581.050.230.25-0.22-1.10
EPS Growth (YoY)
2.55%5.35%53.94%78.02%27.64%33.57%56.70%3.41%5.13%20.69%5.88%-16.19%408.70%365.20%---45.13%-78.87%--

Additional Metrics

Fiscal Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period Ending
Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Free Cash Flow
2,1022,8121,3064,4482,7273,2842,1992,9662,7032,0691,8552,7951,4482,8862,0262,6839953,0131,0951,459
Free Cash Flow Per Share
1.351.800.842.851.752.101.411.901.731.331.191.790.931.851.301.720.641.930.710.97
Dividend Per Share
1.060-2.170-1.030-2.100-1.000-1.970-0.930-1.970-0.930-1.970-
Dividend Growth (YoY)
2.91%-3.33%-3.00%-6.60%-7.53%-0%-0%-0%-3.33%-3.68%-
Gross Margin
83.55%82.52%79.55%81.62%82.89%83.51%85.52%77.29%83.13%82.51%82.70%81.77%82.83%82.49%107.78%72.85%72.17%69.17%83.46%61.92%
Operating Margin
23.46%27.94%21.59%24.11%24.27%26.55%33.32%15.53%21.22%24.57%27.79%17.00%21.51%23.36%50.82%11.34%5.00%13.38%30.61%-5.09%
Profit Margin
16.30%20.15%15.00%16.67%16.95%21.46%10.07%10.53%14.89%17.19%7.98%11.96%15.93%16.57%8.04%14.93%3.34%3.39%-2.89%-16.74%
Free Cash Flow Margin
13.66%18.39%8.42%29.28%18.86%24.17%14.77%21.87%20.89%16.32%15.43%24.32%12.68%26.53%18.08%24.43%9.24%26.45%9.12%14.79%
EBITDA
5,1935,6384,1135,2114,8974,8925,2493,9234,0254,3704,2333,1803,6833,7726,6712,5611,9642,7394,6342,341
EBITDA Margin
33.76%36.88%26.53%34.30%33.87%36.00%35.25%28.92%31.11%34.47%35.20%27.67%32.26%34.67%59.52%23.32%18.23%24.05%38.58%23.73%
D&A For EBITDA
1,5841,3667661,5491,3891,2842871,8171,2791,2558921,2261,2271,2319761,3161,4251,2159582,843
EBIT
3,6094,2723,3473,6623,5083,6084,9622,1062,7463,1153,3411,9542,4562,5415,6951,2455391,5243,676-502
EBIT Margin
23.46%27.94%21.59%24.11%24.27%26.55%33.32%15.53%21.22%24.57%27.79%17.00%21.51%23.36%50.82%11.34%5.00%13.38%30.61%-5.09%
Effective Tax Rate
10.40%21.28%11.41%21.86%21.71%14.14%9.96%21.61%19.57%22.14%-16.59%12.83%20.25%---29.84%--
Revenue as Reported
15,38415,28815,50315,19114,45713,58814,89113,56512,93812,67912,02411,49211,41610,87911,20710,98210,77111,39012,0119,866
SEC Filings: 10-K · 10-Q